Table 2.
Demographical and clinical data of 348 patients with COVID-19 stratified for serum parathyroid hormone (PTH) measurement. Categorical data were presented as n/n or n (%), whereas continuous data were presented as median and range
| Measurement of PTH values | P values | ||
|---|---|---|---|
| No | Yes | ||
| N | 251 | 97 | |
| Age (years) | 68.0 (27.0–95.0) | 69.0 (26.0–93.0) | 0.851 |
| Sex (F/M) | 86/165 | 38/59 | 0.391 |
| BMI (kg/m2) | 25.9 (17.0–46.0) | 27.0 (19.0–53.0) | 0.043 |
| Obesity | 59 (23.5) | 24 (24.7) | 0.808 |
| Arterial hypertension | 136 (54.2) | 27 (27.8) | < 0.001 |
| Diabetes mellitus | 81 (32.3) | 43 (44.3) | 0.035 |
| CAD | 64 (25.5) | 12 (12.4) | 0.008 |
| Active or past cancer | 40 (15.9) | 11 (11.3) | 0.277 |
| COPD | 27 (10.8) | 21 (21.6) | 0.008 |
| CKD | 32 (12.7) | 7 (7.2) | 0.142 |
| ≥ 2 Comorbidities | 91 (36.3) | 15 (15.5) | < 0.001 |
| 25(OH)D (ng/mL) | 10.0 (1.0–39.0) | 21.0 (4.0–67.0) | < 0.001 |
| 25(OH)D < 12 ng/mL | 138 (55.0) | 23 (23.7) | < 0.001 |
| Treatment with vitamin D | 13 (5.2) | 15 (15.5) | 0.003 |
| Corrected calcium (mmol/L) | 2.15 (1.64–2.78) | 2.15 (1.85–2.41) | 0.643 |
| PaO2/FiO2 (mmHG) | 299.0 (46.0–561.0) | 309 (110.0–480.0) | 0.075 |
| Acute hypoxemic respiratory failure at the study entry | 126 (50.2) | 43 (44.3) | 0.326 |
| In-hospital mortality | 47 (18.7) | 17 (17.5) | 0.796 |
BMI body mass index, CAD coronary artery disease, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, F females, M males, PTH parathyroid hormone, 25(OH)D 25hydroxyvitamin D